IOL Chemicals & Pharma Q1 Profit Soars 89.8%
By Business Desk
IOL Chemicals & Pharmaceuticals reports an impressive 89.80% surge in Q1 2026 net profit to Rs 64.40 crore, driven by a 37.08% jump in sales.
IOL Chemicals & Pharmaceuticals recorded a substantial 89.80% surge in its consolidated net profit, reaching Rs 64.40 crore for the quarter ending June 2026. This marks a significant upturn from the Rs 33.93 crore reported in the same period of the previous year.
- Consolidated Net Profit (June 2026): Rs 64.40 crore
- Consolidated Net Profit (June 2025): Rs 33.93 crore
- Net Profit Growth: 89.80%
- Sales (June 2026): Rs 756.26 crore
- Sales (June 2025): Rs 551.69 crore
- Sales Growth: 37.08%
The impressive profit expansion was bolstered by a robust increase in the company’s sales figures. Total sales climbed by 37.08%, amounting to Rs 756.26 crore during the June 2026 quarter. This compares to sales of Rs 551.69 crore registered in the corresponding June 2025 period.
Quarterly Performance Breakdown
The substantial financial growth reflects a strong operational period for IOL Chemicals & Pharmaceuticals. Both the top-line revenue and bottom-line profitability saw significant year-over-year improvements, indicating robust market demand and operational efficiency.
These results highlight a period of aggressive financial expansion for the pharmaceutical firm. The marked increases across key metrics position the company favorably in its sector following the June 2026 quarter’s strong showing.